MTOR and acute myeloid leukemia: We also observed enrichment of an mTOR signature in primary blasts from eight samples from patients with sorafenib-resistant AML (GSE35907) (Figure 4c) and in primary patients AML blasts expressing an FLT3-ITD compared with those lacking the FLT3-ITD (525 AML samples, GSE14468) (Figure 4d).